Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FBI Unveils Science of Anthrax Investigation

By Drug Discovery Trends Editor | August 25, 2008

Most people did not know that the work in Ray Goehner’s materials characterization department at Sandia National Laboratories was contributing important information to the FBI’s investigation of letters containing bacillus anthracis, the spores that cause the disease anthrax. The spores were mailed in the fall of 2001 to several news media offices and to two U.S. senators. Five people were killed.

Sandia’s work demonstrated to the FBI that the form of bacillus anthracis contained in those letters was not a weaponized form, a form of the bacteria prepared to disperse more readily. The possibility of a weaponized form was of great concern to investigators, says Joseph Michael, the principal investigator for the project. This information was crucial in ruling out state-sponsored terrorism.

In fall of 2001, the FBI considered how to best investigate the anthrax letters. The agency convened two blue ribbon exploratory panels, and Sandia’s name came up during both panels for its expertise in electron and ion microscopies and microanalysis over the range of length scales from millimeters down to nanometers. The first spore material from the letters arrived at Sandia in February of 2002.

Sandia faced some uncertainty in working on this type of investigation. Researchers signed nondisclosure agreements and agreed to make themselves available to government agencies on short notice when called to give information.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE